THPO (drug)
Pharmaceutical compound
From Wikipedia, the free encyclopedia
THPO, also known as 4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3(2H)-one, is a relatively weak GABA reuptake inhibitor with some glial selectivity.[1][2] It is a synthetic and conformationally restrained analogue of the GABAA receptor agonist and weak GABA reuptake inhibitor muscimol (found in Amanita muscaria).[1] Unlike muscimol however, THPO is a selective GABA reuptake inhibitor and lacks GABAA receptor affinity.[3][2] The drug penetrates into the brain in newborn mice, but shows only very limited central penetration in animals with fully developed brains.[2] Other structurally related selective GABA reuptake inhibitors include guvacine, nipecotic acid, and tiagabine.[1][2]
- None
| |
| Clinical data | |
|---|---|
| Other names | 4,5,6,7-Tetrahydroisoxazolo[4,5-c]pyridin-3(2H)-one |
| Drug class | GABA reuptake inhibitor |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C6H8N2O2 |
| Molar mass | 140.142 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
- Gaboxadol (THIP)
